Duodenal erosions after eradication of helicobacter pylori infection

Gastrointestinal Endoscopy

Volumn 54, Issue 4, 2001, Pages 448-453

  Shiotani, Akiko ^a,b   Nishioka, Shingo ^a,b   Iguchi, Mikitaka ^a,b   Yanaoka, Kimihiko ^a,b   Okada, Kazuhisa ^a,b   Tamai, Hidyuki ^a,b   Mantani, Yoshihiko ^a,b   Itoh, Hidekazu ^a,b   Graham, David Y ^a,b  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; PEPSINOGEN; PEPSINOGEN II;

ARTICLE; ATROPHIC GASTRITIS; BLOOD; DIGESTIVE TRACT ENDOSCOPY; DUODENUM; DUODENUM ULCER; ESOPHAGUS; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; STOMACH ULCER; TIME;

DUODENAL ULCER; DUODENUM; ENDOSCOPY, DIGESTIVE SYSTEM; ESOPHAGUS; FEMALE; FOLLOW-UP STUDIES; GASTRINS; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PEPSINOGEN A; PEPSINOGEN C; PROSPECTIVE STUDIES; STOMACH ULCER; TIME FACTORS;

EID: 0035491042     PISSN: 00165107     EISSN: None     Source Type: Journal    
DOI: 10.1067/mge.2001.118134     Document Type: Article

References (36)

1. Stolte M. Helicobacter pylori gastritis and gastric MALT-lymphoma. Lancet 1992;339:745-6.
2. NIH consensus development panel on Helicobacter pylori in peptic ulcer disease. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
3. Marshall BJ, Goodwin CS, Warren Jr, Murray R, Blincow ED, Blackbourn SJ, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;1:1437-42.
4. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989;96:615-25.
5. Working party of the European Helicobacter pylori study group. Guidelines for clinical trials in Helicobacter pylori infection. Gut 1997;41(suppl 2):S1-S9.
6. Labenz J, Blum AL, Bayerdvrffer, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
7. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology 2000;118:82-8.
8. Graham DY, Yamaoka Y. H pylori and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Helicobacter 1998;3:145-51.
9. Iijima K, Ohara S, Sekine H, Koike T, Kato K, Asaki S, et al. Curing Helicobacter pylori infection may provoke transient duodenitis via the increase in acid secretion [abstract]. Gastroenterology 1999;116:A194.
10. Samloff IM, Vans K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, pepsinogen II and gastric mucosal histology. A study in relatives of patients with H pylori pernicious anemia. Gastroenterology 1982;83: 204-9.
11. Asaka M, Kimura T, Kudo M, Takeda H, Mitani S, Miyazaki T, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992;102:760-6.
12. Asaka M, Kato M, Kudo M, Meguro T, Kimura T, Miyazaki T, et al. The role of Helicobacter pylori in peptic ulcer disease. Gastroenterol Jpn 1993;28(suppl 5):163-7.
13. Hunter FM, Correa P, Fontham E, Rioz B, Sobhan M, Samloff IM. Serum pepsinogens as markers of response to therapy for Helicobacter pylori gastritis. Dig Dis Sci 1993;38:2081-6.
14. Wagner S, Haruma K, Gladziwa U, Soudah B, Gebel M, Bleck J, et al. Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication. Am J Gastroenterol 1994;89:1211-8.
15. Furuta T, Kaneko E, Baba S, Arai H, Futami H. Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacter pylori. Am J Gastroenterol 1997;92:84-8.
16. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-80.
17. Labenz J, Malfertheiner P. Helicobacter pylori in gastrooesophageal reflux disease: causal agent, independent or protective factor? Gut 1997;41:277-60.
18. Gutienez O, Melo M, Segura AM, Angel A, Genta RM, Graham DY Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997;32:664-8.
19. El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997;113:15-24.
20. El-Serag HB, Sonnenberg A, Jamal MM, Inadomi JM, Crooks LA, Feddersen RM. Corpus gastritis is protective against reflux oesophagitis. Gut 1999;45:181-5.
21. Haruma K, Mihara M, Okamoto E, Kusunoki H, Hananoki M, Tanaka S, et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus-evaluation of 24-h pH monitoring. Aliment Pharmacol Ther 1999;13:155-62.
22. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883-90.
23. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 1999;106:642-9.
24. McDougall NI, Johnston BT, Collins JS, McFarland RJ, Love AH. Three- to 4.5-year prospective study of prognostic indicators in gastro-oesophageal reflux disease. Scand J Gastroenterol 1998;33:1016-22.
25. Wilson LJ, Ma W, Hirschowitz BI. Association of obesity with hiatal hernia and esophagitis. Am J Gastroenterol 1999;94: 2840-4.
26. Samloff IM. Slow moving protease and the seven pepsinogens; Electrophoric demonstration of the existence of eight proteolytic fractions in human gastric mucosa. Gastroenterology 1969;57:659-69.
27. Samloff IM. Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology 1971;61:185-8.
28. Samloff IM, Liebman WM. Cellular localization of group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology 1973;65:36-42.
29. Sipponen F, Samloff IM, Saukkonen NI, Vans K. Serum pepsinogens I and II and gastric mucosal histology after partial gastrectomy. Gut 1985;26:1179-82.
30. El-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995;109:681-91.
31. Moss SF, Calam J. Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori. Gut 1993;34:888-92.
32. Calam J. Helicobacter pylori, acid and gastrin. Eur J Gastroenterol Hepatol 1995;7:310-7.
33. Graham DY. Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease. J Gastroenterol Hepatol 1991;6: 105-13.
34. Harris AW, Gurnmett PA, Misiewicz JJ, Baron JH. The effect of eradication of Helicobacter pylori on gastric acid output in patients with duodenal ulcer [abstract]. Gastroenterology 1995;108:A109.
35. Parente F, Maconi G, Sangaletti O, Minguzzi M, Vago L, Bianchi Porro G. Behaviour of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of Helicobacter pylori in duodenal ulcer patients. A controlled study. Gut 1995;37:210-5.
36. Iijima K, Ohara S, Sekine H, Koike T, Kato K, Asaki S, et al. Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut 2000;46:20-26.